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EDITORIAL
Mast cells find their way to the kidney
Histologically, progressive renal disease is character- tial fibrosis reported by El-Koraie et al [2], as well as in
ized by an interstitial infiltrate of inflammatory cells in all of the earlier studies, the time has come to seriously
association with tubular atrophy and interstitial fibrosis. consider the possibility that mast cells actively contribute
There are many reasons to believe that the mononuclear to renal destruction by fibrosis. Several studies of extra-
cells, especially those of monocytic lineage, play an active renal lesions, such as the cutaneous lesions of scleroderma
role in fibrogenesis even though definitive proof of their and keloid scars, pulmonary fibrosis, cardiac fibrosis, he-
role is still lacking [1]. In this issue of Kidney Interna- patic cirrhosis, rheumatoid arthritis, and myelofibrosis,
tional, El-Koraie et al investigate the presence of mast have also reported a close correlation between mast cells
cells in the interstitium of human kidney biopsies ob- and fibrosis. Based primarily on in vitro studies, mast
tained from patients with chronic glomerulonephritis [2]. cells have been observed to mediate various effects that
Mast cells turn out to be a very interesting population could promote fibrosis. For example, the mast cell–specific
of bone marrow–derived cells that have been largely serine proteases, tryptase and chymase, may stimulate
ignored by the nephrology community. These basophilic collagen synthesis and the processing of procollagen to
leukocytes are characterized by the presence of cyto- fibril-forming collagens. Both proteases can activate
plasmic granules enriched with proteoglycans and prote- some of the latent metalloproteinases. Chymase is also a
ases, including the mast cell–specific proteases, chymase chemoattractant for monocytes and tryptase is a chemoat-
and tryptase. Mast cell precursor cells originate in the tractant and mitogen for fibroblasts. Chymase can con-
bone marrow, circulate in small numbers in the blood, vert angiotensin I into angiotensin II and mediate the
and mature into tissue mast cells within most organs. release of matrix-bound transforming growth factor-
Mast cells are best known for their role in anaphylactic (TGF-). Mast cells also synthesize many products that
allergic reactions following interactions of immunoglob- are not unique to these cells, including histamine, seroto-
ulin E (IgE) with the Fc epsilon receptor 1. Mature tissue nin, proteoglycans, arachidonic acid metabolites, platelet-
mast cells are heterogenous, with at least two phenotypi- activating factor (PAF), and even some extracellular ma-
cally distinct populations identified. In rodents, T-cell– trix proteins. Mast cells may be stimulated to synthesize
dependent mucosal-type mast cells can be distinguished chemokines, cytokines, and growth factors with fibrosis-
from T-cell–independent connective tissue–type mast promoting effects, including TGF-, basic fibroblast
cells by their differential staining with alcian blue-safarin growth factor (bFGF), and tumor necrosis factor-.
and by differences in the content of their granules (hista- Given the strong temporal association between the
mine, proteoglycans, and serine proteases). In humans, it presence of mast cells and renal fibrosis, the next step
is not currently possible to distinguish between mucosal- is to determine whether mast cells actually cause renal
type and connective tissue–type mast cells. Human mast fibrosis. Mice and rats genetically deficient in mast cells
cells are subtyped on the basis of mast cell–specific prote- do exist. Stem cell factor (SCF), also known as kit ligand,
ases. All human mast cells contain tryptase, the major mast cell growth factor, or steel factor, is essential for
mast cell protein constituent, whereas only a subset con- mast cell survival. It binds to the c-kit receptor (CD117),
tains chymase. a member of the type III receptor tyrosine kinase family
Scattered reports of mast cells in the renal interstitium that is encoded by the c-kit proto-oncogene. A number
date back to 1960 [3], and there have been a few recent of rodent genetic mutations have been reported in SCF
studies of mast cells in the interstitium of human kidneys [steel (Sl) mutations] and the c-kit receptor [dominant
with primary glomerular diseases [4–7]. Mast cells have white-spotting (W) mutation that also causes alterations
also been observed in association with renal amyloidosis, of coat color]. Animals carrying these mutant genes are
diabetic nephropathy, chronic allograft rejection, and severely deficient in mast cells. Thus far, studies in ro-
tubulointerstitial nephropathies. Given the strong corre- dents with inherited mutations in the W gene (Ws/Ws
lation between interstitial mast cell number and intersti- rats and W/wv mice) have reported no difference in the
severity of carbon tetrachloride–induced liver fibrosis
[8], murine scleroderma [9], and bleomycin–induced lungKey words: chronic glomerulonephritis, interstitium, renal fibrosis,
stem cell factor. fibrosis [10, 11] in the absence of mast cells at the site
of fibrosis when compared with wild-type mice. Similar 2001 by the International Society of Nephrology
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studies of renal fibrosis have not yet been reported, but cells. Not only does it regulate the migration and survival
it is likely that similar outcomes would be observed. of primitive mast cells, CSF also regulates many of their
However, these negative studies in genetically deficient other activities, including maturation, proliferation, and
mice do not completely exclude an important fibrogenic secretion of mast cell mediators. In an interesting study,
action of local mast cells. Genetic deficiency frequently Kitoh et al reported that serum SCF levels were signifi-
results in compensatory actions by other pathways. Al- cantly elevated in patients with chronic renal failure [12].
ternative experimental approaches might include manip- Whether these high levels are a consequence of decreased
ulations to significantly enhance the number of connec- clearance of this 28,000 to 40,000 dalton glycoprotein
tive tissue mast cells or interventions to selectively inhibit or increased production in unknown. Future studies are
or deplete mast cell fibrogenic mediators. For example, needed to determine what factors up-regulate SCF pro-
if the products of mast cell secretory granules are found duction in the kidney and whether SCF production is
to have significant fibrosis-promoting effects in vivo, the critical factor that recruits and/or maintains mast
mast cell stabilizing therapy may be protective. cells in the renal interstitium.
Although much more work is necessary to establish It is already known that SCF has important biologic
whether mast cells play a pathogenic role in renal fibrosis, effects on nonhematopoietic cells. In addition to gameto-
it seems appropriate to begin to investigate how mast genesis, SCF appears to play a role in melanogenesis and
cells are recruited and retained within the renal intersti- development of the central nervous system. Perhaps it
tium. Whether a significant number of marrow-derived will be shown to also affect renal cells. Using a polyclonal
mast cells actually reside in the normal interstitium like antibody to the SCF receptor, c-kit, El-Koraie et al iden-
resident interstitial macrophages is currently unknown. tified a few receptor-positive renal interstitial cells in the
If they do, proliferation of resident mast cells might diseased kidneys [2]. These preliminary findings do not
account, at least in part, for the increased number of mast exclude the possibility that resident kidney cells may also
cells in damaged kidneys. Alternatively, this increase in express c-kit and respond to SCF. One previous study
mast cell number might be the consequence of increased reported c-kit expression by human renal tubules [13].
survival due to the up-regulated expression of anti-apo- Mast cells have found their way to the kidney. In fact,
ptotic or pro-survival factors such as SCF. However, it this old observation has been largely ignored despite a
is equally feasible that interstitial mast cells that are growing body of evidence suggesting that these cells have
associated with renal fibrosis are recruited from circulat- significant profibrotic effects. With the added evidence
ing mast cell precursors. Several mast cell chemoattrac- that SCF, the critical mast cell survival factor, is also
tants have been identified, including SCF, but also plate-
expressed in chronically damaged human kidneys, the
let-derived growth factor AB, vascular endothelial growth
time has come to establish whether these cells are criti-factor, bFGF, complement component C1q, regulated
cally involved in renal fibrosis. Given the unique aspectsupon activation, normal T cell expressed and presumed
of mast cell biology, selective targeting of these cellssecreted (RANTES), TGF-, interleukin-3, PAF, fibro-
and/or their secretory products may be a feasible futurenectin, and laminin. Given this long and certainly incom-
therapeutic strategy if a critical link is established be-plete list, it is likely that the regulation of mast cell recruit-
tween mast cells and renal scarring.ment will be found to be complex, with compensation
readily induced in the absence of a single factor. None-
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